Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×Selective serotonin reuptake inhibitors (SSRIs)

Updated · Methodology

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs list selective serotonin reuptake inhibitors (SSRIs) among the drugs that can potentiate its effect. Escitalopram is not among the examples, but the class is named without restriction, and the escitalopram SmPC itself classes it as an SSRI (AEMPS). According to the escitalopram labels, escitalopram may alter the effect of oral anticoagulants. SSRIs also raise the risk of bleeding on their own, and anticoagulants may add to this risk (escitalopram SmPC, AEMPS; escitalopram prescribing information, US Food and Drug Administration, FDA). The documents contain no study with acenocoumarol. Racemic citalopram 40 mg a day for 21 days did not change warfarin pharmacokinetics but raised the prothrombin time by 5%. The clinical significance of this is unknown (escitalopram prescribing information, FDA). Based on in vitro studies, the Spanish escitalopram SmPC calls it a weak inhibitor of CYP2C19, which takes part in the metabolism of the R-enantiomer of acenocoumarol together with CYP1A2 (the main enzyme is CYP2C9). The US label found no in vitro inhibition of CYP2C9 or CYP2C19 (escitalopram and acenocoumarol SmPCs, AEMPS; FDA).

Symptoms

The main risk is bleeding. Bleeding into the skin, such as ecchymosis and purpura, has been reported with selective serotonin reuptake inhibitors (SSRIs). Gastrointestinal bleeding, including rectal bleeding, appears among the adverse effects of escitalopram (escitalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the US label, such bleeding ranges from ecchymoses, haematomas, nosebleeds and petechiae to life-threatening haemorrhage (escitalopram prescribing information, US Food and Drug Administration, FDA). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. In patients on an oral anticoagulant, monitor coagulation closely when escitalopram is started and when it is stopped (escitalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when escitalopram is added and when it is stopped (acenocoumarol SmPCs, AEMPS). The Spanish escitalopram SmPC recommends caution with oral anticoagulants and in patients prone to bleeding. The US label says to inform patients of the increased risk of bleeding (escitalopram SmPC, AEMPS; escitalopram prescribing information, US Food and Drug Administration, FDA). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol

Other interactions with Escitalopram